Form 4: Boston Scientific Executive Sells Shares Under Pre-Arranged Trading Plan

Jeffrey B. Mirviss, EVP & President of Peripheral Interventions at Boston Scientific, sold 1,510 shares of common stock at $105.35 per share under a pre-established Rule 10b5-1 trading plan.

Summary

• On February 19, 2025, Jeffrey B. Mirviss, EVP & President of Peripheral Interventions at Boston Scientific, sold 1,510 shares of Boston Scientific common stock.
• The sale was executed at a price of $105.35 per share.
• The transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024.
• Following the transaction, Mirviss directly owns 33,129 shares of Boston Scientific common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an executive stock sale under a pre-arranged trading plan, indicating a neutral sentiment.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies and are often related to personal financial planning. The use of a 10b5-1 trading plan allows insiders to sell shares without being accused of trading on non-public information.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, but the pre-arranged nature of the sale mitigates concerns about insider trading.

Key Dates

Keywords

Form 4, Boston Scientific, BSX, Jeffrey B. Mirviss, Executive Stock Sale, Rule 10b5-1, Peripheral Interventions